SCA
ELOS

SAC Capital Advisors’s Syneron Medical Ltd ELOS Stock Holding History

SAC Capital Advisors’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-85,000
Closed -$1.06M – 1396
2014
Q1 		$1.06M Buy
+85,000
New +$1.01M 0.01% 931

Other funds holding ELOS

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $480M AUM 32.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SAC Capital Advisors's ELOS Position: Q2 2014 in Review

SAC Capital Advisors sold out of Syneron Medical Ltd (ELOS) in Q2 2014, closing a stake of 85,000 shares — an estimated $1.06M sold.

SAC Capital Advisors first reported a position in ELOS in Q1 2014 and held it in 1 quarter. The position peaked at $1.06M in Q1 2014. 61 funds tracked by Wall St. Rank hold ELOS as of Q2 2014.

  • SAC Capital Advisors reported no remaining Syneron Medical Ltd position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 85,000 Syneron Medical Ltd shares in Q2 2014, an estimated $1.06M.
  • SAC Capital Advisors first reported a position in Syneron Medical Ltd in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Syneron Medical Ltd position peaked at $1.06M in Q1 2014.
  • 61 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.